Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 18/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28114750 | 1.00 | PDE2A (0.51) | PDE2AEPHX2PDE1APDE4DSLC7A5 | |
| SCHEMBL19946337 | 0.85 | PDE2A (0.50) | PDE2AEPHX2SLC7A5 | |
| SCHEMBL18045497 | 0.81 | EPHX1 (0.43) | PDE2AEPHX2SLC7A5 | |
| SCHEMBL28700452 | 0.79 | TRPM8 (0.43) | PDE2A | |
| SCHEMBL28700451 | 0.79 | TRPM8 (0.43) | PDE2A | |
| SCHEMBL19946332 | 0.78 | PDE2A (0.53) | PDE2AEPHX2SLC7A5 | |
| SCHEMBL18036164 | 0.78 | PDE2A (0.59) | PDE2AEPHX2PDE1APDE4DSLC7A5 | |
| SCHEMBL16563727 | 0.78 | PDE2A (0.59) | PDE2AEPHX2PDE1APDE4DSLC7A5 | |
| SCHEMBL19946338 | 0.78 | PDE2A (0.64) | PDE2AEPHX2 | |
| Hydrochloric Acid SCHEMBL16563850 | 0.77 | PDE2A (0.58) | PDE2AEPHX2PDE1APDE4DSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104245698-B | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2016-11-30 | — | — | CN | disclosed |
| US-20160159808-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159808-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE3A, PDE5A | PDE2A 1/4885EPHX2 862/4885PDE1A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.